Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
afuresertib + enzalutamide
- Development stage
- Preclinical
- Lead developer
- Laekna
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**afuresertib + enzalutamide** is an experimental combination therapy for prostate cancer. **Afuresertib** is a selective, oral AKT inhibitor that targets the PI3K/AKT pathway, which is frequently dysregulated in prostate cancers, especially those with PTEN loss. **Enzalutamide** is a non-steroidal antiandrogen that inhibits androgen receptor (AR) signaling, an established driver of prostate cancer. This combination is being studied for use in metastatic castration-resistant prostate cancer (mCRPC), particularly with alterations in the PI3K/AKT pathway. The rationale is simultaneous blockade of both the AR signaling and survival pathways (AKT), which may overcome resistance to single-agent therapy and improve efficacy.
02
Targets
AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)AR (Adrenergic receptors)
Beyond the preview
Go deeper on afuresertib + enzalutamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on afuresertib + enzalutamide.